Literature DB >> 17478439

Obesity and prostate cancer: making sense out of apparently conflicting data.

Stephen J Freedland1, Elizabeth A Platz.   

Abstract

Both obesity and prostate cancer are epidemic in Western society. Although initial epidemiologic data appeared conflicting, recent studies, especially large prospective studies published in the past 6-12 months, have clarified the association between obesity and prostate cancer. The aim of this paper is to review the epidemiologic data linking obesity and prostate cancer, with an emphasis on new data published since 2005. A PubMed search was done on the keywords, "prostate cancer" and "obesity." Relevant articles and their references were reviewed for data on the association between obesity and prostate cancer. Recent data suggest that obesity is associated with reduced risk of nonaggressive disease but increased risk of aggressive disease. This may in part be explained by an inherent bias in our ability to detect prostate cancer in obese men (lower prostate-specific antigen values and larger sized prostates making biopsy less accurate for finding an existing cancer). Ultimately, this leads to increased risk of cancer recurrence after primary therapy and increased risk of prostate cancer mortality. The biologic causes of these associations are likely multifactorial, although the lower testosterone levels among obese men appear to be one of the most promising explanations. The association between obesity and prostate cancer is complex. Emerging data suggest a differential effect of obesity by disease aggressiveness: obesity may reduce the risk of nonaggressive disease while it may promote aggressive disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478439     DOI: 10.1093/epirev/mxm006

Source DB:  PubMed          Journal:  Epidemiol Rev        ISSN: 0193-936X            Impact factor:   6.222


  74 in total

Review 1.  Time course of risk factors in cancer etiology and progression.

Authors:  Esther K Wei; Kathleen Y Wolin; Graham A Colditz
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

2.  The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted County study.

Authors:  Lauren P Wallner; Hal Morgenstern; Michaela E McGree; Debra J Jacobson; Jennifer L St Sauver; Steven J Jacobsen; Aruna V Sarma
Journal:  Urology       Date:  2010-11-20       Impact factor: 2.649

3.  Uric acid: a modulator of prostate cells and activin sensitivity.

Authors:  Febbie Sangkop; Geeta Singh; Ely Rodrigues; Elspeth Gold; Andrew Bahn
Journal:  Mol Cell Biochem       Date:  2016-02-24       Impact factor: 3.396

Review 4.  Dietary interventions in prostate cancer.

Authors:  Wendy Demark-Wahnefried
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

Review 5.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

6.  Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.

Authors:  Scott P Kelly; Barry I Graubard; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook
Journal:  J Natl Cancer Inst       Date:  2016-10-20       Impact factor: 13.506

7.  Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.

Authors:  R Asmar; J L Beebe-Dimmer; K Korgavkar; G R Keele; K A Cooney
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-08-21       Impact factor: 5.554

8.  Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate.

Authors:  Andrew Rundle; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-23       Impact factor: 4.254

9.  Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database.

Authors:  Robert J Hamilton; William J Aronson; Martha K Terris; Christopher J Kane; Joseph C Presti; Christopher L Amling; Stephen J Freedland
Journal:  J Urol       Date:  2008-03-17       Impact factor: 7.450

10.  Timing of supplementation of selenium and isoflavones determines prostate cancer risk factor reduction in rats.

Authors:  Jessica R Tolman; Edwin D Lephart; Kenneth Dr Setchell; Dennis L Eggett; Merrill J Christensen
Journal:  Nutr Metab (Lond)       Date:  2008-11-10       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.